EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery and Optimization of Ergosterol Peroxide Derivatives as Novel Glutaminase 1 Inhibitors for the Treatment of Triple-Negative Breast Cancer

Ran Luo, Haoyi Zhao, Siqi Deng, Jiale Wu, Haijun Wang, Xiaoshan Guo, Cuicui Han, Wenkang Ren, Yinglong Han, Jianwen Zhou, Yu Lin, Ming Bu iD

Molecules · 2024

DOI: 10.3390/molecules29184375 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Ran Luo und 11 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Qiqihar Medical University, Qiqihar 161006, China. Hauptthemen laut MEDLINE: Glutaminase, Triple Negative Breast Neoplasms, Molecular Docking Simulation, Cell Proliferation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Heilongjiang Provincial Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this study, novel ergosterol peroxide (EP) derivatives were synthesized and evaluated to assess their antiproliferative activity against four human cancer cell lines (A549, HepG2, MCF-7, and MDA-MB-231). Compound 3g exhibited the most potent antiproliferative activity, with an IC50 value of 3.20 µM against MDA-MB-231. This value was 5.4-fold higher than that of the parental EP. Bioassay optimization further identified 3g as a novel glutaminase 1 (GLS1) inhibitor (IC50 = 3.77 µM). In MDA-MB-231 cells, 3g reduced the cellular glutamate levels by blocking the glutamine hydrolysis pathway, which triggered reactive oxygen species production and induced caspase-dependent apoptosis. Molecular docking indicated that 3g interacts with the reaction site of the variable binding pocket by forming multiple interactions with GLS1. In a mouse model of breast cancer, 3g showed remarkable therapeutic effects at a dose of 50 mg/kg, with no apparent toxicity. Based on these results, 3g could be further evaluated as a novel GLS1 inhibitor for triple-negative breast cancer (TNBC) therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlutaminaseTriple Negative Breast NeoplasmsMolecular Docking SimulationCell ProliferationAntineoplastic AgentsErgosterolHumansAnimalsMiceCell Line, TumorFemaleApoptosisEnzyme InhibitorsXenograft Model Antitumor AssaysReactive Oxygen SpeciesStructure-Activity Relationship

Stichwörter der Autor:innen

GLS1 inhibitorsTNBCantitumorergosterol peroxide derivatives

Substanzen

GlutaminaseAntineoplastic AgentsErgosterolEnzyme Inhibitorsergosterol-5,8-peroxideReactive Oxygen SpeciesGLS protein, human

Autor:innen und Institutionen

  • College of Pharmacy, Qiqihar Medical University, Qiqihar 161006, China.
  • College of Pharmacy, Hainan University, Haikou 570228, China.
  • Research Institute of Medicine & Pharmacy, Qiqihar Medical University, Qiqihar 161006, China.

ORCID-Profile: Ming Bu

Förderung

  • Heilongjiang Provincial Natural Science Foundation of China

Zitieren

APA

Luo, R., Zhao, H., Deng, S., Wu, J., Wang, H., Guo, X., Han, C., Ren, W., Han, Y., Zhou, J., Lin, Y., & Bu, M. (2024). Discovery and Optimization of Ergosterol Peroxide Derivatives as Novel Glutaminase 1 Inhibitors for the Treatment of Triple-Negative Breast Cancer. Molecules. https://doi.org/10.3390/molecules29184375

Vancouver

Luo R, Zhao H, Deng S, Wu J, Wang H, Guo X, et al. Discovery and Optimization of Ergosterol Peroxide Derivatives as Novel Glutaminase 1 Inhibitors for the Treatment of Triple-Negative Breast Cancer. Molecules. 2024. doi:10.3390/molecules29184375

BibTeX
@article{Luo2024,
  author = {Luo, Ran and Zhao, Haoyi and Deng, Siqi and Wu, Jiale and Wang, Haijun and Guo, Xiaoshan and Han, Cuicui and Ren, Wenkang and Han, Yinglong and Zhou, Jianwen and Lin, Yu and Bu, Ming},
  title = {Discovery and Optimization of Ergosterol Peroxide Derivatives as Novel Glutaminase 1 Inhibitors for the Treatment of Triple-Negative Breast Cancer},
  journal = {Molecules},
  year = {2024},
  doi = {10.3390/molecules29184375}
}
Kostenlos starten →